Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights

LA JOLLA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the third quarter 2019 and recent business highlights.